Zu-Guo Zheng

Dr. Zu-Guo Zheng


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 December 2022 in Cell Metabolism
Verified
Journal Article
Closed access
ZZZu-Guo Zheng
Zu-Guo Zheng
YXYin-Yue Xu
Yin-Yue Xu
WLWen-Ping Liu
Wen-Ping Liu
YZYang Zhang
Yang Zhang
CZChong Zhang
Chong Zhang
PLPing Li
Ping Li

21 December 2022 in Pharmacological Research
Verified
Journal Article
Open access
QZQian-Qian Zhou
Qian-Qian Zhou
HXHai-Tao Xiao
Hai-Tao Xiao
FYFan Yang
Fan Yang
YWYong-Dan Wang
Yong-Dan Wang
PLPing Li
Ping Li
ZZZu-Guo Zheng
Zu-Guo Zheng
The development and application of traditional drugs represented by small molecule chemical drugs and biological agents, especially inhibitors, have become the mainstream drug development. In recent years, targeted protein degradation (TPD) technology has become one of the most promising methods to remove specific disease-related proteins using cell self-destruction mechanisms. Many different TPD strategies are emerging based on the ubiquitin-proteasome system (UPS) and the autophagy-lysosomal pathway (ALP), including but not limited to proteolysis-targeting chimeras (PROTAC), molecular glues (MG), lysosome targeting chimeras (LYTAC), chaperone-mediated autophagy (CMA)-targeting chimeras, autophagy-targeting chimera (AUTAC), autophagosome-tethering compound (ATTEC), and autophagy-targeting chimera (AUTOTAC). The advent of targeted degradation technology can change most protein targets in human cells from undruggable to druggable, greatly expanding the therapeutic prospect of refractory diseases such as metabolic syndrome. Here, we summarize the latest progress of major TPD technologies, especially in metabolic syndrome and look forward to providing new insights for drug discovery.

21 June 2023 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
HXHai-Tao Xiao
Hai-Tao Xiao
JJJing Jin
Jing Jin
ZZZu-Guo Zheng
Zu-Guo Zheng
As the first histone acetyltransferase to be cloned and identified in yeast, general control non-depressible 5 (GCN5) plays a crucial role in epigenetic and chromatin modifications. It has been extensively studied for its essential role in regulating and causing various diseases. There is mounting evidence to suggest that GCN5 plays an emerging role in human diseases and its therapeutic potential is promising. In this paper, we begin by providing an introduction GCN5 including its structure, catalytic mechanism, and regulation, followed by a review of the current research progress on the role of GCN5 in regulating various diseases, such as cancer, diabetes, osteoporosis. Thus, we delve into the various aspects of GCN5 inhibitors, including their types, characteristics, means of discovery, activities, and limitations from a medicinal chemistry perspective. Our analysis highlights the importance of identifying and creating inhibitors that are both highly selective and effective inhibitors, for the future development of novel therapeutic agents aimed at treating GCN5-related diseases.

11 January 2025 in Cell Reports
Verified
Journal Article
Open access
ZZZu-Guo Zheng
Zu-Guo Zheng
YZYi-Ping Zhang
Yi-Ping Zhang
XZXiao-Yu Zhang
Xiao-Yu Zhang
MQMeng-Yao Qin
Meng-Yao Qin
YXYin-Yue Xu
Yin-Yue Xu
HYHua Yang
Hua Yang
Sterols target sterol-sensing domain (SSD) proteins to lower cholesterol and circulating and hepatic triglyceride levels, but the mechanism remains unclear. In this study, we identify acyl-coenzyme A (CoA) synthetase long-chain family member 1 (ACSL1) as a direct target of ergosterol (ES). The C-terminal domain of ACSL1 undergoes conformational changes from closed to open, and ES may target the drug-binding pocket in the acetyl-CoA synthetase-like domain 1 (ASLD1) of ACSL1 to stabilize the closed conformation and maintain its activity. Moreover, ES is mainly enriched in the mitochondria and promotes fatty acid β-oxidation through ACSL1 allosteric activation. Structure-activity relationship analysis reveals how different structural sterols interact with the sterol-sensing domain-containing protein (SCAP) and ACSL1, explaining their regulatory effects on lipid metabolism. Moreover, our findings reveal that the combination of SCAP inhibitor 25-hydroxycholesterol (25-HC) and ES has a stronger lipid-lowering effect than alone.

22 June 2020 in Nanoscale
Verified
Journal Article
Closed access
PDF file
LMLingchang Meng
Lingchang Meng
XZXian Zheng
Xian Zheng
ZZZu-Guo Zheng
Zu-Guo Zheng
ZZZhen Zhao
Zhen Zhao
LWLai Wang
Lai Wang
HLHui-Jun Li
Hui-Jun Li
Drug-induced liver injury (DILI) is increasingly recognized as one of the most challenging global health problems. Conventional in vitro detection methods not only lack specificity and sensitivity but also cannot achieve real-time, straightforward visualization of hepatotoxicity in vivo. Liver-specific miR122 has been observed to be a superior and sensitive biomarker for DILI diagnosis. Herein, a sensitive upconverting nanoprobe synthesized with upconversion nanoparticles (UCNPs) and gold nanorods (GNR) was designed to diagnose hepatotoxicity in vivo. After injection, the nanoprobes accumulated in the liver and were activated by miR122, and the signal amplification technology fully yielded luminescent amplification; hence, the detection sensitivity was improved. Because of the high tissue penetration capability of near-infrared light, this nanoprobe can achieve real-time in situ detection, thereby providing a novel technology for precise biological and medical analysis.

30 June 2025 in Metabolism and Target Organ Damage
Verified
Journal Article
Open access
PDF file
JZJing Zhu
Jing Zhu
HXHai-Tao Xiao
Hai-Tao Xiao
QWQiu-Yi Wu
Qiu-Yi Wu
XSXue-Xue Shao
Xue-Xue Shao
YMYu-Fan Meng
Yu-Fan Meng
ZZZu-Guo Zheng
Zu-Guo Zheng
Aim: Sterol regulatory element-binding proteins (SREBPs) are key transcription factors driving de novo lipid synthesis (DNL) and associated metabolic disorders. This study aims to investigate whether bilirubin, a potential SREBP inhibitor, alleviates lipid accumulation and insulin resistance by targeting the HSP90β/SREBP pathway. Methods: In vitro, HL-7702 cells were treated with bilirubin to assess lipid-lowering effects and SREBP-related gene expression. In vivo, high-fat diet (HFD)-induced obese mice received bilirubin intervention for 6 weeks. Lipid profiles, insulin sensitivity, hepatic SREBP protein levels, and downstream gene expression were analyzed. Mechanistic studies focused on HSP90β activity modulation by bilirubin. Results: Bilirubin significantly reduced lipid accumulation in HL-7702 cells and downregulated SREBPs and their target genes. In HFD-fed mice, bilirubin attenuated obesity, hepatic steatosis, and insulin resistance, accompanied by suppressed SREBP protein levels and expression of target genes. Mechanistically, bilirubin inhibited SREBP activation by targeting HSP90β. Conclusion: Bilirubin ameliorates metabolic syndrome via the HSP90β/SREBP axis, providing a novel therapeutic strategy for lipid metabolism disorders and insulin resistance. These findings highlight bilirubin’s potential as a pharmacological agent against metabolic diseases.